MJ Clinical Training

MJ Clinical Training logo

Mounjaro shows great results in treating Obstructive Sleep Apnoea

Understanding Obstructive Sleep Apnoea (OSA)

Obstructive Sleep Apnoea (OSA) is a common sleep disorder where your airway repeatedly gets blocked during sleep, leading to interrupted breathing. This can cause loud snoring, choking or gasping for air, and excessive daytime sleepiness. Untreated OSA can lead to serious health issues like heart disease and stroke.

How is OSA Treated?

Treating OSA involves keeping the airway open during sleep. This can be achieved through lifestyle changes, oral appliances, surgery, and the most effective method, Continuous Positive Airway Pressure (CPAP) therapy.

What is CPAP?

CPAP stands for Continuous Positive Airway Pressure. This therapy involves wearing a mask over your nose and/or mouth while you sleep. The CPAP machine delivers a constant stream of air to keep your airway open, preventing interruptions in breathing. CPAP therapy helps you get better sleep, reduces daytime sleepiness, and lowers the risk of health problems associated with OSA.

Exciting New Treatments: Mounjaro

Researchers are always looking for new ways to treat OSA. One promising new treatment is Mounjaro (tirzepatide), which is a medication that acts as a dual agonist for GLP-1 and GIP. Mounjaro was originally developed to manage diabetes but has shown potential in treating OSA.

How Mounjaro Might Help with OSA

Mounjaro helps regulate blood sugar and appetite, leading to weight loss, which can reduce fat around the airway and lessen the severity of OSA. According to a recent article on Medscape, clinical trials have shown that Mounjaro can significantly reduce sleep disruptions in patients with OSA, improving sleep quality and overall well-being.

Tirzepatide Plus CPAP: A Winning Combination

Dr. Sanjay R. Patel highlighted the importance of integrating obesity management into OSA treatment. He noted that many patients abandon CPAP therapy within three years. An effective medication like tirzepatide can be a valuable tool in managing obesity, leading to significant reductions in AHI (apnea–hypopnea index – used to measure the severity of a patient’s sleep apnoea) events and improvements in systolic blood pressure. This suggests that combining tirzepatide with CPAP therapy might enhance cardiovascular health and overall treatment outcomes for OSA patients.

The Future of OSA Treatment

While CPAP remains the primary treatment for OSA, Mounjaro offers an exciting new option, especially for those who struggle with CPAP therapy. Continued research will help determine how Mounjaro can best be used to treat OSA, potentially offering better outcomes and a higher quality of life for patients.

For more information, you can visit the Medscape article on Mounjaro’s impact on sleep disruptions.

Semaglutide (Wegovy) vs. Tirzepatide (Mounjaro): Which is the Better Weight Loss Medication? 

There are no direct head-to-head trials between semaglutide (Wegovy) and tirzepatide (Mounjaro). So, what we have to date is like comparing two world-class boxers and asking who is the best, when they have never actually fought each other. This study uses statistical analysis to virtually “match” and “pair-up” participants in different trials to provide a better comparison of the effectiveness of the two drugs.

Read More